Meda acquires rights to Nalox in Europe

Meda acquires rights to Nalox in Europe

Meda has acquired exclusive licensing rights to Nalox (treatment of
fungal nail infections/nail psoriasis) from Moberg Derma AB. Within a
short time span, Meda has established Nalox as the market leader in the
Nordic region. The new agreement covers several major European
countries, such as Germany, France, the UK, Spain, Austria, the
Netherlands and Belgium.

“We continue to strengthen our position in dermatology in Europe. We're
looking forward to successful launches in new markets”, says Anders
Lönner, Meda CEO.
 

For further inquiries, please contact:
Anders Larnholt, Vice President Corporate Development & IR      ph: +46
709-458 878

MEDA AB (publ) is a leading international specialty pharma company.
Meda's products are sold in 120 countries worldwide and the company is
represented by its own organizations in 50 countries. The Meda share is
listed under Large Cap on the Nasdaq OMX Nordic Stock Exchange in
Stockholm. Find out more, visit www.meda.se (http://www.meda.se/).

Forward-looking Statements
This press release is not an offer to sell or a solicitation to buy
shares in Meda. This press release also contains certain forward-looking
statements with respect to certain future events and Meda's potential
financial performance. These forward-looking statements can be
identified by the fact that they do not relate only to historical or
current facts, and may sometimes include words such as “may”, “will”,
“seek”, “anticipate”, “expect”, “estimate”, “intend”, “plan”,
“forecast”, “believe” or other words of similar meaning. These forward
looking statements reflect the current expectations on future events of
the management at the time such statements are made, but are made
subject to a number of risks and uncertainties. In the event such risks
or uncertainties materialize, Meda's results could be materially
affected. The risks and uncertainties include, but are not limited to,
risks associated with the inherent uncertainty of pharmaceutical
research and product development, manufacturing and commercialization,
the impact of competitive products, patents, legal challenges,
government regulation and approval, Meda's ability to secure new
products for commercialization and/or development and other risks and
uncertainties detailed from time to time in Meda AB's interim or annual
reports, prospectuses or press releases. Listeners and readers are
cautioned that no forward-looking statement is a guarantee of future
performance and that actual result could differ materially from those
contained in the forward-looking statements. Meda does not intend, nor
undertakes, to update any such forward looking statements.